Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $35.7 million.

  • Exagen's Cash & Equivalents rose 6201.5% to $35.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.7 million, marking a year-over-year increase of 6201.5%. This contributed to the annual value of $22.0 million for FY2024, which is 3961.58% down from last year.
  • Latest data reveals that Exagen reported Cash & Equivalents of $35.7 million as of Q3 2025, which was up 6201.5% from $30.0 million recorded in Q2 2025.
  • In the past 5 years, Exagen's Cash & Equivalents ranged from a high of $118.1 million in Q1 2021 and a low of $11.2 million during Q1 2025
  • Moreover, its 5-year median value for Cash & Equivalents was $36.5 million (2023), whereas its average is $55.6 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 7676.61% in 2021, then plummeted by 5897.44% in 2025.
  • Exagen's Cash & Equivalents (Quarter) stood at $99.4 million in 2021, then plummeted by 37.26% to $62.4 million in 2022, then tumbled by 41.51% to $36.5 million in 2023, then plummeted by 39.62% to $22.0 million in 2024, then surged by 62.01% to $35.7 million in 2025.
  • Its Cash & Equivalents was $35.7 million in Q3 2025, compared to $30.0 million in Q2 2025 and $11.2 million in Q1 2025.